Professor Des Richardson

E:  des.richardson@bosch.org.au T:  +61 2 9036 6548 F:  +61 2 9351 3429 D06 - Blackburn Building The University of Sydney NSW 2006 Australia

• Research interests
• Competitive grants
• Publications

Research interests

Current national competitive grants

Publications

2010

Saletta, F, Rahmanto, Y, Richardson, D. The Translational Regulator eIF3a: The Tricky eIF3 Subunit!. Biochimica et biophysica acta. 2010; :

Merlot, A, Pantarat, N, Lovejoy, D, Kalinowski, D, Richardson, D. Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer. Molecular pharmacology. 2010; :

Jansson, P, Sharpe, P, Bernhardt, P, Richardson, D. Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity. Journal of medicinal chemistry. 2010; :

Bendova, P, Mackova, E, Haskova, P, Vavrova, A, Jirkovsky, E, Sterba, M, Popelova, O, Kalinowski, D, Kovarikova, P, Vavrova, K, Richardson, D, Simunek, T. Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical research in toxicology. 2010; :

Kovacevic, Z, Kalinowski, D, Lovejoy, D, Quach, P, Wong, J, Richardson, D. Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current drug delivery. 2010; :

Richardson, D, Lane, D, Becker, E, Huang, M, Whitnall, M, Rahmanto, Y, Sheftel, A, Ponka, P. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proceedings of the National Academy of Sciences of the United States of America. 2010; :

Richardson, D, Huang, M, Whitnall, M, Becker, E, Ponka, P, Suryo Rahmanto, Y. The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. Journal of molecular medicine (Berlin, Germany). 2010; 88:323-9

Saletta, F, Suryo Rahmanto, Y, Noulsri, E, Richardson, D. Iron Chelator-Mediated Alterations in Gene Expression: Identification of Novel Iron-Regulated Molecules that are Molecular Targets of HIF-1{alpha} and p53. Molecular pharmacology. 2010; 77:443-58

Liu, J, Obando, D, Schipanski, L, Groebler, L, Witting, P, Kalinowski, D, Richardson, D, Codd, R. Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload. Journal of medicinal chemistry. 2010; 53:1370-82

2009

Huang, M, Becker, E, Whitnall, M, Rahmanto, Y, Ponka, P, Richardson, D. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:16381-16386

Yu, Y, Kalinowski, D, Kovacevic, Z, Siafakas, A, Jansson, P, Stefani, C, Lovejoy, D, Sharpe, P, Bernhardt, P, Richardson, D. Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of medicinal chemistry. 2009; 52:5271-94

Suryo, R, Richardson, D. Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype. Biochimica et biophysica acta. 2009; 1793:1210-7

Richardson, D, Kalinowski, D, Lau, S, Jansson, P, Lovejoy, D. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochimica et biophysica acta. 2009; 1790:702-17

Peslova, G, Petrak, J, Kuzelova, K, Hrdy, I, Halada, P, Kuchel, P, Soe-Lin, S, Ponka, P, Sutak, R, Becker, E, Huang, M, Suryo Rahmanto, Y, Richardson, D, Vyoral, D. Hepcidin, the hormone of iron metabolism, is bound specifically to {alpha}-2-macroglobulin in blood. Blood. 2009; 113:6225-36

Rosemary Siafakas, A, Richardson, D. Growth arrest and DNA damage-45 alpha (GADD45alpha). The international journal of biochemistry & cell biology. 2009; 41:986-9

Richardson, D, Kalinowski, D, Richardson, V, Sharpe, P, Lovejoy, D, Islam, M, Bernhardt, P. 2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity. Journal of medicinal chemistry. 2009; 52:1459-70

Assinder, S, Dong, Q, Mangs, H, Richardson, D. Pharmacological Targeting of the Integrated AKT, PTEN and TGF-{beta} Pathways in Prostate Cancer. Molecular pharmacology. 2009; 75:429-36

Bernhardt, P, Sharpe, P, Islam, M, Lovejoy, D, Kalinowski, D, Richardson, D. Iron Chelators of the Dipyridylketone Thiosemicarbazone Class: Precomplexation and Transmetalation Effects on Anticancer Activity. Journal of medicinal chemistry. 2009; 52:407-15

Assinder, S, Dong, Q, Kovacevic, Z, Richardson, D. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal. 2009; 417:411-421

Stariat, J, Kovaríková, P, Klimes, J, Lovejoy, D, Kalinowski, D, Richardson, D. HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009; 877:316-322

Bohlken, A, Cheung, B, Bell, J, Koach, J, Smith, S, Sekyere, E, Thomas, W, Norris, M, Haber, M, Lovejoy, D, Richardson, D, Marshall, G. ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells. British Journal of Cancer. 2009; 100:96-105

Noulsri, E, Richardson, D, Lerdwana, S, Fucharoen, S, Yamagishi, T, Kalinowski, D, Pattanapanyasat, K. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. American Journal of Hematology. 2009; 84:170-176

Sheftel, A, Richardson, D, Prchal, J, Ponka, P. Mitochondrial Iron Metabolism and Sideroblastic Anemia. Acta Haematologica. 2009; 122:120-133

Lovejoy, D, Yu, Y, Richardson, D. Chelators as Anti-Cancer Drugs. In: Encyclopedia of Cancer. Germany: Springer 2009. p. 0.

Mladĕnka, P, Kalinowski, D, Haskova, P, Bobrovová, Z, Hrdina, R, Simůnek, T, Nachtigal, P, Semecký, V, Vávrová, J, Holeckova, M, Palicka, V, Mazurová, Y, Jansson, P, Richardson, D. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chemical research in toxicology. 2009; 22:208-217

2008

Lim, S, Raftery, M, Cai, H, Hsu, K, Yan, W, Hseih, H, Watts, R, Richardson, D, Thomas, S, Perry, M, Geczy, C. S-nitrosylated S100A8: novel anti-inflammatory properties. Journal of Immunology. 2008; 181:5627-5636

Kovacevic, Z, Fu, D, Richardson, D. The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. Biochimica et biophysica acta. 2008; 1783:1981-92

Opletalova��, V, Kalinowski, D, Vejsova��, M, Kunes, J, Pour, M, Jampi��lek, J, Buchta, V, Richardson, D. Identification and Characterization of Thiosemicarbazones with Antifungal and Antitumor Effects: Cellular Iron Chelation Mediating Cytotoxic Activity. Chemical research in toxicology. 2008; 21:1878-89

Whitnall, M, Rahmanto, Y, Sutak, R, Xu, X, Becker, E, Mikhael, M, Ponka, P, Richardson, D. The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:9757-62

Lim, C, Kalinowski, D, Richardson, D. Protection Against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts using Novel Iron Chelators of the PCIH Class. Molecular pharmacology. 2008; 74:225-35

Long, S, Jirků, M, Mach, J, Ginger, M, Sutak, R, Richardson, D, Tachezy, J, Lukeš, J. Ancestral roles of eukaryotic frataxin: mitochondrial frataxin function and heterologous expression of hydrogenosomal Trichomonas homologues in trypanosomes. Molecular microbiology. 2008; 69:94-109

Sutak, R, Lesuisse, E, Tachezy, J, Richardson, D. Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends in microbiology. 2008; 16:261-8

Sutak, R, Xu, X, Whitnall, M, Kashem, M, Vyoral, D, Richardson, D. Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism. Proteomics. 2008; 8:1731-1741

Richardson, D, Lok, H. The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes. Biochimica et Biophysica Acta. 2008; 1780:638-651

Xu, X, Sutak, R, Richardson, D. Iron Chelation by Clinically Relevant Anthracyclines: Alteration in Expression of Iron-Regulated Genes and Atypical Changes in Intracellular Iron Distribution and Trafficking. Molecular pharmacology. 2008; 73:833-44

Kalinowski, D, Sharpe, P, Bernhardt, P, Richardson, D. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. Journal of Medicinal Chemistry. 2008; 51:331-344

Bernhardt, P, Wilson, G, Sharpe, P, Kalinowski, D, Richardson, D. Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry. 2008; 13:107-19

Lovejoy, D, Yu, Y, Richardson, D. Chelators as anti-cancer drugs. In: Encyclopedia of Cancer. Germany: Springer 2008. p. 0.

Rahmanto, Y, Sekyere, E, Dunne, L, Richardson, D. The function of the membrane-bound transferrin homologue, melanotransferin (melanoma tumour antigen p97). In: Iron Metabolism and Disease. United States: Transworld Research 2008. p. 219-239.

Farnaud, S, Amini, M, Rapisarda, C, Cammack, R, Bui, T, Drake, A, Evans, R, Rahmanto, Y, Richardson, D. Biochemical and spectroscopic studies of human melanotransferrin (MTf): electron-paramagnetic resonance evidence for a difference between the iron-binding site of MTf and other transferrins. The international journal of biochemistry & cell biology. 2008; 40:2739-45

Rahmanto, Y, Richardson, D. The Physiological and Pathophysiological Roles of Melanotransferrin. Germany: VDM Verlag, 2008.

2007

Kalinowski, D, Sharpe, P, Bernhardt, P, Richardson, D. Design, Synthesis, and Characterization of New Iron Chelators with Anti-Proliferative Activity: Structure-Activity Relationships of Novel Thiohydrazone Analogues. Journal of medicinal chemistry. 2007; 50:6212-25

Podeszwa, B, Niedbala, H, Polanski, J, Musiol, R, Tabak, D, Finster, J, Serafin, K, Milczarek, M, Wietrzyk, J, Boryczka, S, Mol, W, Jampilek, J, Dohnal, J, Kalinowski, D, Richardson, D. Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic & medicinal chemistry letters. 2007; 17:6138-6141

Suryo Rahmanto, Y, Dunn, L, Richardson, D. Identification of Distinct Changes in Gene Expression after Modulation of Melanoma Tumor Antigen p97 (Melanotransferrin) in Multiple Models In Vitro and In Vivo. Carcinogenesis. 2007; 28:2172-83

Suryo Rahmanto, Y, Dunn, L, Richardson, D. The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark - from iron metabolism to tumorigenesis. Oncogene. 2007; 26:6113-24

Yu, Y, Kovacevic, Z, Richardson, D. Tuning Cell Cycle Regulation With an Iron Key. Cell cycle (Georgetown, Tex.). 2007; 6:1982-94

Kalinowski, D, Yu, Y, Sharpe, P, Islam, M, Liao, Y, Lovejoy, D, Kumar, N, Bernhardt, P, Richardson, D. Design, Synthesis, and Characterization of Novel Iron Chelators: Structure-Activity Relationships of the 2-Benzoylpyridine Thiosemicarbazone Series and Their 3-Nitrobenzoyl Analogues as Potent Antitumor Agents. Journal of medicinal chemistry. 2007; 50:3716-29

Fu, D, Richardson, D. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood. 2007; 110:752-761

Nurtjahja-Tjendraputra, E, Fu, D, Phang, J, Richardson, D. Iron Chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood. 2007; 109:4045-54

Kalinowski, D, Richardson, D. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chemical research in toxicology. 2007; 20:715-20

Mrkvicková, Z, Kovaríková, P, Klimes, J, Kalinowski, D, Richardson, D. Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity. Journal of pharmaceutical and biomedical analysis. 2007; 43:1343-1351

Richardson, D, Suryo Rahmanto, Y. Differential regulation of the Menkes and Wilson disease copper transporters by hormones: an integrated model of metal transport in the placenta. The Biochemical journal. 2007; 402:e1-3

Musiol, R, Jampilek, J, Kralova, K, Richardson, D, Kalinowski, D, Podeszwa, B, Finster, J, Niedbala, H, Palka, A, Polanski, J. Investigating biological activity spectrum for novel quinoline analogues. Bioorganic & medicinal chemistry. 2007; 15:1280-1288

Dunn, L, Rahmanto, Y, Richardson, D. Iron uptake and metabolism in the new millennium. Trends in cell biology. 2007; 17:93-100

Jerebtsova, M, Richardson, D, Nekhai, S, Gordeuk, V, Ray, P, Debebe, Z, Kurantsin-Mills, J, Ammosova, T, Charles, S, Niu, X. Iron chelators ICL670 and 311 inhibit HIV-1 transcription. VIROLOGY. 2007; 367:324-333

Sharpe, P, Richardson, D, Bernhardt, P, Chin, P. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. DALTON TRANSACTIONS. 2007; 30:3232-3244

2006

Kovacevic, Z, Richardson, D. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis. 2006; 27:2355-66

Yu, Y, Wong, J, Lovejoy, D, Kalinowski, D, Richardson, D. Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12:6876-83

Richardson, D, Sharpe, P, Lovejoy, D, Senaratne, D, Kalinowski, D, Islam, M, Bernhardt, P. Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity. Journal of medicinal chemistry. 2006; 49:6510-6521

Dunn, L, Sekyere, E, Rahmanto, Y, Richardson, D. The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis. 2006; 27:2157-69

Whitnall, M, Howard, J, Ponka, P, Richardson, D. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:14901-6

Richardson, D, Lovejoy, D. "Iron mining" if to inhibit tumor growth. Blood. 2006; 108:2140-2140

Whitnall, M, Richardson, D. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Seminars in pediatric neurology. 2006; 13:186-97

Watts, R, Hawkins, C, Ponka, P, Richardson, D. Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:7670-7675

Sekyere, E, Dunn, L, Suryo Rahmanto, Y, Richardson, D. Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in-vivo. Blood. 2006; 107:2599-601

Sekyere, E, Dunn, L, Rahmanto, Y, Richardson, D. Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood. 2006; 107:2599-2601

Davies, N, Rahmanto, Y, Chitambar, C, Richardson, D. Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. The Journal of pharmacology and experimental therapeutics. 2006; 317:153-62

Lovejoy, D, Kalinowski, D, Bernhardt, P, Richardson, D. PCTH: a novel orally active chelator for the treatment of iron overload disease. Hemoglobin. 2006; 30:93-104

Rahmanto, Y, Sekyere, E, Dunne, L, Richardson, D. Identification of melanotransferin (p97) associated genes using in vitro and in vivo models. Free Radical Research. 2006; 40:S55

Sekyere, E, Dunne, L, Rahmanto, Y, Richardson, D. Role of melanotransferin in iron metabolism: studies using targeted gene disruption in vivo. Blood. 2006; 107:2599-2601

2005

Kalinowski, D, Richardson, D. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacological reviews. 2005; 57:547-583

2004

Yuan, J, Lovejoy, D, Richardson, D. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004; 104:1450-8

Walcourt, A, Loyevsky, M, Lovejoy, D, Gordeuk, V, Richardson, D. Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. The international journal of biochemistry & cell biology. 2004; 36:401-407

2003

Bernhardt, P, Caldwell, L, Lovejoy, D, Richardson, D. Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta crystallographica. Section C, Crystal structure communications. 2003; 59:o629-33

Liang, S, Richardson, D. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis. 2003; 24:1601-14

Chaston, T, Richardson, D. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. American journal of hematology. 2003; 73:200-10

Wong, C, Richardson, D. Beta-thalassaemia: emergence of new and improved iron chelators for treatment. The international journal of biochemistry & cell biology. 2003; 35:1144-9

Le, N, Richardson, D. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis. 2003; 24:1045-58

Lovejoy, D, Richardson, D. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Current medicinal chemistry. 2003; 10:1035-49

Chaston, T, Richardson, D. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry. 2003; 8:427-38

Kwok, J, Richardson, D. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Molecular pharmacology. 2003; 63:849-61

Becker, E, Lovejoy, D, Greer, J, Watts, R, Richardson, D. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. British journal of pharmacology. 2003; 138:819-830

Richardson, D. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?. Expert opinion on investigational drugs. 2003; 12:235-45

Watts, R, Ponka, P, Richardson, D. Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron. The Biochemical journal. 2003; 369:429-40

Richardson, D. The biogenesis of [Fe-S] clusters: the role of the unorthodox ABC ATPase, SufC, and the wider implications for understanding iron metabolism. Redox report : communications in free radical research. 2003; 8:125-7

Chaston, T, Lovejoy, D, Watts, R, Richardson, D. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9:402-14

2002

Le, N, Richardson, D. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochimica et biophysica acta. 2002; 1603:31-46

Kwok, J, Richardson, D. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Molecular pharmacology. 2002; 62:888-900

Food, M, Sekyere, E, Richardson, D. The soluble form of the membrane-bound transferrin homologue, melanotransferrin, inefficiently donates iron to cells via nonspecific internalization and degradation of the protein. European journal of biochemistry / FEBS. 2002; 269:4435-45

Richardson, D. Deferiprone: greater efficacy at depleting myocardial than hepatic iron?. Lancet. 2002; 360:501-2

Lovejoy, D, Richardson, D. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood. 2002; 100:666-76

Watts, R, Richardson, D. The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner. European journal of biochemistry / FEBS. 2002; 269:3383-92

Richardson, D. Iron chelators as therapeutic agents for the treatment of cancer. Critical reviews in oncology/hematology. 2002; 42:267-81

Becker, E, Greer, J, Ponka, P, Richardson, D. Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood. 2002; 99:3813-22

Kwok, J, Richardson, D. The iron metabolism of neoplastic cells: alterations that facilitate proliferation?. Critical reviews in oncology/hematology. 2002; 42:65-78

Le, N, Richardson, D. Ferroportin1: a new iron export molecule?. The international journal of biochemistry & cell biology. 2002; 34:103-8

Richardson, D. Therapeutic potential of iron chelators in cancer therapy. Advances in experimental medicine and biology. 2002; 509:231-49

2001

Gao, J, Richardson, D. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood. 2001; 98:842-50

Richardson, D, Mouralian, C, Ponka, P, Becker, E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochimica et biophysica acta. 2001; 1536:133-40

Thomas, S, Salahifar, H, Mashima, R, Hunt, N, Richardson, D, Stocker, R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. Journal of immunology (Baltimore, Md. : 1950). 2001; 166:6332-40

Richardson, D. The controversial role of deferiprone in the treatment of thalassemia. The Journal of laboratory and clinical medicine. 2001; 137:324-9

Richardson, D. Iron and gallium increase iron uptake from transferrin by human melanoma cells: further examination of the ferric ammonium citrate-activated iron uptake process. Biochimica et biophysica acta. 2001; 1536:43-54

Richardson, D, Dean, R. Does free extracellular iron exist in haemochromatosis and other pathologies, and is it redox active?. Clinical science (London, England : 1979). 2001; 100:237-8

Watts, R, Richardson, D. Nitrogen monoxide (no) and glucose: unexpected links between energy metabolism and no-mediated iron mobilization from cells. The Journal of biological chemistry. 2001; 276:4724-32

Richardson, D. Proton transfer and ferredoxin I: the secrets of redox-driven proton transfer between solvent and a buried iron-sulphur cluster. Redox report : communications in free radical research. 2001; 6:11-3

Becker, E, Richardson, D. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. The international journal of biochemistry & cell biology. 2001; 33:1-10

Richardson, D. Cloning of the ferrireductase that may be involved in iron transport in the small intestine: revisiting Crane's controversial oxidoreductase. Redox report : communications in free radical research. 2001; 6:133-5